The Hematopoietic Stem Cell Antigen, CD34, Is Not Expressed on the Malignant Cells in Multiple Myeloma

Autologous stem cell transplantation has become an important therapy in multiple myeloma (MM). To develop adequate autograft purging methods, it is necessary to determine whether antigens expressed on early hematopoietic progenitors exist on malignant cells. The Ig heavy chain produced by the MM cel...

Full description

Saved in:
Bibliographic Details
Published in:Blood 1994-11, Vol.84 (10), p.3283-3290
Main Authors: Vescio, Robert A., Hong, Charlie H., Cao, Jin, Kim, Austin, Schiller, Gary J., Lichtenstein, Alan K., Berenson, Ronald J., Berenson, James R.
Format: Article
Language:English
Subjects:
Antigens, CD - biosynthesis
Antigens, CD - genetics
Antigens, CD34
Base Sequence
Biological and medical sciences
Bone Marrow - immunology
Bone Marrow - pathology
Cell Separation
DNA Primers
Gene Expression
Genes, Immunoglobulin
Hematopoietic Stem Cells - immunology
Humans
Immunodeficiencies. Immunoglobulinopathies
Immunoglobulin Heavy Chains - genetics
Immunoglobulin Heavy Chains - immunology
Immunoglobulin Variable Region - genetics
Immunoglobulin Variable Region - immunology
Immunoglobulinopathies
Immunopathology
Medical sciences
Molecular Sequence Data
Multiple Myeloma - immunology
Multiple Myeloma - pathology
Neoplasm Staging
Oligonucleotides, Antisense
Polymerase Chain Reaction
Sensitivity and Specificity
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Autologous stem cell transplantation has become an important therapy in multiple myeloma (MM). To develop adequate autograft purging methods, it is necessary to determine whether antigens expressed on early hematopoietic progenitors exist on malignant cells. The Ig heavy chain produced by the MM cells shows evidence of prior somatic mutation without intraclonal diversity. As a result, this sequence can be used as a specific marker to detect ail members of the malignant clone. The Ig heavy chain sequence expressed by the MM cells was obtained in five patients with advanced disease. Patient specific oligonucleotide primers were designed based on the complementarity determining regions (CDR) of each MM Ig sequence and used to amplify DNA by polymerase chain reaction for the detection of malignant cells. A highly purified collection of CD34+ cells was obtained after passage of the initial bone marrow cells through an immunoadsorption column and fluorescence-activated cell sorting. Despite an assay sensitivity of 1 tumor cell in 2,500 to 44,000 normal cells, none of the CD34+ samples showed product with the myeloma-specific CDR primers. Therefore, positive selection for cells bearing this antigen should yield a tumor-free autograft capable of providing hematopoietic recovery after myeloablative chemotherapy.
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V84.10.3283.3283